Lv6
2890 积分 2022-06-29 加入
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
2个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
2个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
2个月前
已完结
Gastric cancer
4个月前
已完结
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
5个月前
已完结
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
5个月前
已完结
Claudin 18.2 as a novel therapeutic target
5个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
6个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
6个月前
已完结
皖公网安备34019202002308
